Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes. - Wikidata - awgldk - TriplyDB

Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes.

Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes.

http://www.wikidata.org/entity/Q35671828

about

Pharmacology and Clinical Drug Candidates in Redox Medicine The Role of Hydrogen Sulfide in Renal System Role of NADPH Oxidase in Metabolic Disease-Related Renal Injury: An Update Store-operated calcium entry and diabetic complications Mononuclear-macrophages but not neutrophils act as major infiltrating anti-leptospiral phagocytes during leptospirosis.Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease.Regulation of Nox enzymes expression in vascular pathophysiology: Focusing on transcription factors and epigenetic mechanisms.Mechanisms of bradykinin-induced expression of connective tissue growth factor and nephrin in podocytes.Metabolomics Reveals a Key Role for Fumarate in Mediating the Effects of NADPH Oxidase 4 in Diabetic Kidney Disease Asymmetric Dimethylarginine Limits the Efficacy of Simvastatin Activating Endothelial Nitric Oxide Synthase.Drug discovery in focal and segmental glomerulosclerosis Pathophysiology of gadolinium-associated systemic fibrosis Diabetes and Kidney Disease: Role of Oxidative Stress.APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db/db mice from renal injury.Tubular atrophy in the pathogenesis of chronic kidney disease progression.Scar management in burn injuries using drug delivery and molecular signaling: Current treatments and future directions.Canonical Transient Receptor Potential 6 Channel: A New Target of Reactive Oxygen Species in Renal Physiology and Pathology.Hydrogen Sulfide in Renal Physiology and Disease.Targeting of NADPH oxidase in vitro and in vivo suppresses fibroblast activation and experimental skin fibrosis.The next generation of therapeutics for chronic kidney disease Targeting inflammation in diabetic kidney disease: early clinical trials.Therapeutic potential of NADPH oxidase 1/4 inhibitors.Free radical scavenging decreases endothelin-1 excretion and glomerular albumin permeability during type 1 diabetes.Novel avenues for treating diabetic nephropathy: new investigational drugs.Centrality of bone marrow in the severity of gadolinium-based contrast-induced systemic fibrosis.Serotonin and Its Receptor as a New Antioxidant Therapeutic Target for Diabetic Kidney Disease Diabetic Nephropathy: a Tangled Web to Unweave.NADPH Oxidase 4 at the Nexus of Diabetes, Reactive Oxygen Species, and Renal Metabolism.A novel pan-Nox inhibitor, APX-115, protects kidney injury in streptozotocin-induced diabetic mice: possible role of peroxisomal and mitochondrial biogenesis.FL-926-16, a novel bioavailable carnosinase-resistant carnosine derivative, prevents onset and stops progression of diabetic nephropathy in db/db mice.Hydrogen sulfide inhibits high glucose-induced NADPH oxidase 4 expression and matrix increase by recruiting inducible nitric oxide synthase in kidney proximal tubular epithelial cells.NADPH oxidase-2 mediates zinc deficiency-induced oxidative stress and kidney damage.Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy.Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy.Schwann cell TRPA1 mediates neuroinflammation that sustains macrophage-dependent neuropathic pain in mice.The role of the Nox4-derived ROS-mediated RhoA/Rho kinase pathway in rat hypertension induced by chronic intermittent hypoxia.K+ deficiency caused defects in renal tubular cell proliferation, oxidative stress response, tissue repair and tight junction integrity, but enhanced energy production, proteasome function and cellular K+ uptake.Inhibition of Nox4-dependent ROS signaling attenuates prostate fibroblast activation and abrogates stromal-mediated pro-tumorigenic interactions.Nox4 is a Target for Tuberin Deficiency Syndrome.Glomerular Endothelial Cells Stress and Cross-Talk With Podocytes in the Development of Diabetic Kidney Disease.

P2860

Q26785525-A7FAB3D8-5482-4FA2-8C9B-6B3934C493BF Q28066719-D077BAA9-2D58-4899-81B8-9CAE70736B3A Q28074668-28DFC514-A6EA-41C4-93CA-9E97F7FCC0CB Q28085037-8E44C917-DE98-4E33-BFE1-2AE50BC0CBDC Q33898193-8DE246F2-9368-402A-9787-FEFEF7C68B96 Q34550600-5521E78F-26F9-4338-9C25-9146915E01DC Q35849697-153BC102-E5BC-44D7-A2F2-9A472DACF920 Q36345943-17789444-D96B-4B0F-9E85-3FE9266DD3F4 Q36514979-8BB5C55C-9E12-4094-B8DC-10E06048218B Q36831934-687E0345-85FA-4D06-93C8-599D67746BEA Q36924116-8AB162CA-FB65-45A5-AB87-CA20E90422C3 Q37139482-E4E9663B-A3E4-4C6B-B2C3-94958CA612AF Q37349206-9CFEA4E2-EAAD-4928-9E73-4A505E71A8CB Q38406031-3D59BDF3-923A-4212-BCF2-88D78FCFAA90 Q38553671-6927A7CF-C99A-4A57-A75C-7E45B5176918 Q38649653-58599131-AEBF-458B-84FA-DB1281239479 Q38758929-18379106-3EF6-45E7-8703-8671891422DA Q38785627-572F8E11-FA90-41A8-B60F-B6CC96E8861A Q38826355-A87C4F38-09E8-4EA2-9515-9622266CF283 Q38845590-2C04C971-2937-44D3-85D4-7D3113E86BE7 Q38857166-E96A8F4F-72A1-4649-975C-AE0A0F768715 Q38858553-60AA3E3F-2C97-4D8D-BCEE-B17A548B8189 Q39048549-15516144-0658-4ABE-BEC4-3FF6E854D2D5 Q39170387-5C445395-81B1-426F-884D-DD7AF7915DDF Q39738492-8CF44C25-6A45-4C94-B07D-3174F5860B9B Q41452150-BF21A8A6-E6BD-404A-995B-6FB6838474D3 Q41993558-B3234BA3-C2BA-447C-A395-9539F87A9ADA Q43023265-34E20D2E-9045-406B-A279-EC0B60ED539C Q46271441-0B9F259C-B54C-49D9-B400-82AF6D916411 Q46279581-890E65B9-E2D8-4715-87C1-A9FA6EDE0F64 Q46419349-F85A4F7F-1894-4A8A-874C-A3878FB19CA2 Q46465429-B401A2E4-F7E5-49BD-B3D8-443B5C5866E2 Q46616439-D997F643-89A8-4CE3-A7E5-A10F3DADB82E Q46648044-2E517D80-3E6B-4FEB-8971-E7742693B582 Q47101699-5C119AEB-E58D-44C5-8B18-06C735417958 Q47775594-61AA3F21-0616-47CC-8876-C934568F127A Q47935999-09E7AA26-E41A-4077-A7C7-FF68678ACDC8 Q50020648-08DBB915-C1E6-4D2F-A38A-B0ECEA363DB1 Q52371377-DB1CA4C6-B0EB-4D69-A375-A41D31D7DEEA Q52599406-6C117327-F434-4B1C-815B-24294A661FE9

P2860

Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes.

http://www.wikidata.org/entity/Q35671828

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Targeting NADPH oxidase with a ...... pathology in type 1 diabetes.

@ast

Targeting NADPH oxidase with a ...... pathology in type 1 diabetes.

@en

type

label

Targeting NADPH oxidase with a ...... pathology in type 1 diabetes.

@ast

Targeting NADPH oxidase with a ...... pathology in type 1 diabetes.

@en

prefLabel

Targeting NADPH oxidase with a ...... pathology in type 1 diabetes.

@ast

Targeting NADPH oxidase with a ...... pathology in type 1 diabetes.

@en

P1433

Q35671828-D09568E8-4DA5-4125-967F-C3D3B0B0D83B

P1476

Q35671828-27977E9E-2C1C-4E1A-8119-94E935649D3F

P2093

Q35671828-38A35C9B-6174-4489-B668-904BC144B750

Q35671828-4C586DA5-802C-42D0-A536-95EFE6C57951

Q35671828-50E3BC89-B07D-4906-9F5A-576102EB3E7C

Q35671828-54BE1652-DB36-4665-B836-3B39A75BC210

Q35671828-68D8EA45-08C4-4D80-A50B-F52004A687A0

Q35671828-BA269285-8652-4D44-A520-C3B86D83FB60

Q35671828-C9C75178-A199-4173-8E3A-803BABB0B5CE

Q35671828-CF6BBB14-5D42-452D-A1F9-47E630C36F00

Q35671828-D90459C7-565A-4808-86FB-A11F8CDFE94E

Q35671828-F10A7316-435F-4267-A288-F9C5E4A5655C

P2860

Q35671828-04F954BA-4F3A-4629-BFD3-6391ADDF314D

Q35671828-08C9BF19-B4C6-4662-8C00-FAAE25E4DB85

Q35671828-0C92BDCE-649E-4A6A-9111-60FA3FB9989F

Q35671828-165C5950-54CA-4EF0-AC87-9FEBBC961044

Q35671828-1E5BB350-D16E-40D4-80EC-62A6E1BDE7D3

Q35671828-1F4223D0-C6ED-4785-87B5-A0621483FF50

Q35671828-216D410E-3341-46F6-B922-A8C6C0FCBEC6

Q35671828-2200643F-D20D-4659-80E9-731DA44025D5

Q35671828-259C78A4-55B1-4060-AA20-116BBE5A7674

Q35671828-27827746-385D-41CC-AC22-904FDA5F64CD

P304

Q35671828-5C071D90-D89E-42EB-80E2-F6C3150B5D2A

P31

Q35671828-B065CF7A-0257-4557-AAF4-82A418064CBC

P356

Q35671828-0BD36886-D6DA-4559-820E-5DE51B57DEE7

P433

Q35671828-87489E26-B9F0-4E8E-B87F-6916F0A25338

P478

Q35671828-0C1C48FD-6E92-442E-86A9-83F59F97E3CA

P577

Q35671828-1DB7D2D6-74C5-43E9-9702-AEBC4C5AF5AF

P5875

Q35671828-FE20DB57-3C67-46F3-B09E-2CE2387C47BD

P698

Q35671828-FFE679AD-3084-48A7-8B73-B51D610BE0B3

P921

Q35671828-C2D60E50-CDE9-44DE-8F3B-DDB848625944

P932

Q35671828-DFD7D81D-5545-46A7-895F-5ED46DD33CA2

P356

AJPRENAL.00396.2014

P1433

American Journal of Physiology - Renal Physiology

P1476

Targeting NADPH oxidase with a ...... pathology in type 1 diabetes.

@en

P2093

Cédric Szyndralewiez

http://www.w3.org/2001/XMLSchema#string

Doug-Yoon Lee

http://www.w3.org/2001/XMLSchema#string

Francesca Bruno

http://www.w3.org/2001/XMLSchema#string

Hanna E Abboud

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Barnes

http://www.w3.org/2001/XMLSchema#string

Karen Block

http://www.w3.org/2001/XMLSchema#string

Khaled Khazim

http://www.w3.org/2001/XMLSchema#string

Paolo Fanti

http://www.w3.org/2001/XMLSchema#string

Rita C Cavaglieri

http://www.w3.org/2001/XMLSchema#string

Sachin Thakur

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting NADPH oxidases in vascular pharmacology

Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system

The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology

Subcellular localization of Nox4 and regulation in diabetes

NADPH oxidase, NOX1, mediates vascular injury in ischemic retinopathy.

Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy.

CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice.

Mouse models of diabetic nephropathy.

NADPH oxidases regulate CD44 and hyaluronic acid expression in thrombin-treated vascular smooth muscle cells and in atherosclerosis.

Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo.

P304

F1276-87

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPRENAL.00396.2014

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

308

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272078490

http://www.w3.org/2001/XMLSchema#string

P698

25656366

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

P932

4451325

http://www.w3.org/2001/XMLSchema#string